Human calprotectin, a potent anticancer with minimal side effect

Iranian Journal of Cancer Prevention

Volumn 2, Issue 4, 2009, Pages 183-188

  Rezaei, Tavirani M ^a,b   Zali, H ^a   Nasiri, S ^b   Shokrgozar, M A ^c  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c PASTEUR INSTITUTE OF IRAN   (Iran)

Author keywords

Etoposide; Human calprotectin; Side effect

Indexed keywords

ANTINEOPLASTIC AGENT; CALGRANULIN; ETOPOSIDE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CHROMATOGRAPHY; CONTROLLED STUDY; CULTURE MEDIUM; CYTOTOXICITY; HUMAN; HUMAN CELL; NEUTROPHIL; SKIN FIBROBLAST; STOMACH ADENOCARCINOMA; TEMPERATURE;

EID: 77953442960     PISSN: 20082401     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Shibata F, Ito A, Ohkuma Y, Mitsui K. Mitogenic activity of S100A9 (MRP-14). Biol Pharm Bull. 2005; 28:2312-14.
2. Yui S, Nakatani Y, Mikami M. Calprotectin (S100A8/S100A9), An inflammatory protein complex from neutrophils with a broad apoptosis-inducing activity. J Biol Pharm Bull.2003; 26: 753-60.
3. Nakatani Y, Yamazaki M, Chazin WJ, Yui S. Regulation of S100A8/A9 (calprotectin) binding to tumor cells by zinc ion and its implication for apoptosis-inducing activity. Mediators Inflamm. 2005;24: 280-92.
4. Pakarinen M, Koivusalo A, Natunen J, Ashorn M, Karikoski R, Aitola P, Rintala R, Kolho K. P027 fecal calprotectin mirrors inflammation of the pulled through ileum and bowel function after restorative proctocolectymy for rediatric onset ulceractive colitis. J Crohn's Colitis Supplements. 2009; 3(1):8.
5. Yui S, Mikami M, Yamazaki M. Induction of apoptotic cell death in mouse lymphoma and human leukemia cell lines by a calcium-binding protein complex, calprotectin, derived from inflammatory peritoneal exudate cells. J Leukoc Biol. 1995; 58: 650-658.
6. Champaiboon C, Sappington KJ, Guenther BD, Ross KF, Herzberg MC. Calprotectin S100A9 Calcium-binding Loops I and II Are Essential for Keratinocyte Resistance to Bacterial Invasion. J Bio Chem. 2009; 284: 7078-90.
7. Sohnle PG, Hunter MJ, Hahn B, Chazin WJ. Zinc- reversible antimicrobial activity of recombinant calprotectin (migration inhibitory factor-related proteins 8 and 14). J Infect Dis. 2000; 182:1272-5.
8. Yui S, Nakatani Y, Hunter M J, Chazin W J, Yamazaki M. Implication of extracellular zinc exclusion by recombinant human calprotectin (MRP8 and MRP14) from target cells in its apoptosis-inducing activity. Mediators Inflamm. 2002; 11: 165-72.
9. Zali H, Marashi SA, Rezaei-Tavirani M, Toossi P, Rahmati-Roodsari M, Shokrgozar MA. On the mechanism of apoptosis-inducing activity of human calprotectin: Zinc sequestration, induction of a signaling pathway, or something else? Med. Hypotheses. 2007; 68(5):1012-15.
10. Marashi SA, Rezaei-Tavirani M, Zali H, Shokrgozar MA. Mitochondrial DNA might be influenced in calprotectin- induced cell death. Exper and Clinic Sciences Inter J, 2008; 7:163-8.
11. Tugizov S, Berline J, Herrera R, Penaranda ME, Nakagawa M, Palefsky J. Inhibition of human papillomavirus type 16 E7 phosphorylation by the S100 MRP-8/14 protein complex. J Virol. 2002; 79:1099-1112.
12. Wong EV, Schaefer AW, Landreth G, Lemmon V.Casein kinase II phosphorylates the neural cell adhesion molecule L1. J. Neurochem. 1996; 66: 779-86.
13. Chen Y, Su YH, Wang CH, Wu JM, Chen JC, Tseng SH. Induction of apoptosis and cell cycle arrest in glioma cells by GL331 (a topoisomerase II inhibitor). Anticancer Res. 2005; 25: 4203-8.
14. Hande KR. Etoposide: four decades of development of a topoisomerase II inhibitor. Eur. J Cancer. 1998; 34: 1514-21.
15. Barker CR, McNamara AV, Rackstraw SA, Nelson ED, White MR, Watson AJ, Jenkins JR. Inhibition of Hsp90 acts synergistically with topoisomerase II poisons to increase the apoptotic killing of cells due to an increase in topoisomerase II mediated DNA damage. Nucleic Acids Res. 2006; 34:1148-57.
16. McClendon AK, Osheroff N. The geometry of DNA supercoils modulates topoisomerase-mediated DNA cleavage and enzyme response to anticancer drugs. Biochem. 2006; 745: 3040-50.
17. Duca M, Guianvarc'h D, Oussedik K, Halby L, Garbesi A, Dauzonne D, Monneret C, Giovannangeli N, Arimondo PB. Molecular basis of the targeting of topoisomerase II-mediated DNA cleavage by etoposide derivatives conjugated to triplex-forming oligonucleotides. Nucleic Acids Res. 2006; 34: 1900-11.
18. Friedrich K, Wieder T, Von CH, Radetzki S, Janicke S, Schulze-Osthoff K, Dorken B, Daniel PT. Overexpression of caspase-3 restores sensitivity for drug-induced apoptosis in breast cancer cell lines with acquired drug resistance. Oncogene. 2001; 20: 2749-60.
19. Liu S, Wu Q, Ye XF, Cai JH, Huang ZW, Su WJ. Induction of apoptosis by TPA and VP-16 is through the translocation of TR3. World J Gastroenterol. 2002; 8: 446-50.
20. Feliu J, Gonzalez MB, Zamora P, Garcia PA, Garcia CG, Blanco E, Belon J, Garrido P, Jara C, Ruiz A, Vincent JM, Espinosa E. Experience of oncopaz cooperative group with oral fluoropyrimidines in tumors of the stomach, lung, head and neck, and breast. Oncology. 1997; 54: 30-37.
21. Sortibran AN, Tellez MG, Rodriguez-Arnaiz R. Genotoxic profile of inhibitors of topoisomerases I (camptothecin) and II (etoposide) in a mitotic recombination and sex-chromosome loss somatic eye assay of Drosophila melanogaster. Mutat Res. 2006; 604:83-90.
22. Marigny K, Aubin F, Burgot G, Gall E, Gandemer V. Particular cutaneous side effects with etoposide-containing courses: is VP16 or etoposide phosphate responsible? Cancer Chemother Pharmacol. 2005; 55:244-50.
23. Muller G, Kerkhoff C, Hankowitz J, Pataki M, Kovacs E, Lackner KJ, Schmitz G. Effects of purinergic agents on human mononu-clear phagocytes are differentiation dependent. Implications for athero-genesis, Arterioscler. Thromb. 1993; 13: 1317-26.
24. van den Bos C, Rammes A, Vogl T, Boynton R, Zaia J, Sorg C, Roth J. Copurification of P6, MRP8, and MRP14 from human granulocytes and separation of individual proteins. Protein Expr Purif. 1998; 13: 313-18.
25. Francis D, Rapid RL. Colorometric assay for cell growth and survival: modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J Immunol Meth. 1986; 89: 271-7.
26. Stahl S, Kasimir-Bauer M, Harstrick A. Down-regulation of topoisomerase II by camptothecin does not prevent additive activity of the topoisomerase II inhibitor etoposide in vitro. Anticancer Drugs. 1997; 8: 671-6.
27. Aisner J, Musanti R, Beers S, Smith S, Locsin S, Rubin EH. Sequencing topotecan and etoposide plus cisplatin to overcome topoisomerase I and II resistance: a pharmacodynamically based Phase I trial. Clin Cancer Res. 2003; 9: 2504-9.
28. Walker PR, Youdal T, Leblanc J, Whitfield JF, Sikorska M. Topoisomerase II-reactive chemotherapeutic drugs induce apoptosis in thymocytes. Cancer Res. 1991; 51: 1078-85.
29. Seiter K. Toxicity of the topoisomerase II inhibitors. Expert Opin Drug Saf. 2005; 4: 219-34.
30. Gullatte MM, Graves T. Advances in antineoplastic therapy. Oncol Nurs Forum. 1990; 17: 867-76.
31. Zali H, Rezaei-Tavirani M, Kariminia A, Yousefi R, Shokrgozar MA. Evaluation of Growth Inhibitory and Apoptosis Inducing Activity of Human Calprotectin on the 188 Human Gastric Cell Line (AGS). Iranian Biomed J. 2008; 12 (1): 7-14.
32. Doljanski F. The sculpturing role of fibroblast-like cells in morphogenesis. Perspect Biol Med. 2004; 47(3):339-56.